ACR17 Good News – Ankylosing Spondylitis and Spondyloarthritis

Save

The following is a collection of AS/SpA-specific mentions culled from RheumNow's coverage of the Annual ACR 2017 meeting in San Diego.

J&J Hit with a $247 Million Verdict over Metal-on-Metal Hip Replacements

Save

Reuters reports that a federal jury has ordered Johnson & Johnson and its DePuy Orthopaedics division to pay $247 million settlment to six patients who suffered from its defective Pinnacle, metal-on-metal, hip implants. in the US. J&J says it will  appeal this decision.

The RheumNow Week in Review - 17 November 2017

Save

Dr. Jack Cush reviews the news and highlights from the past week on RheumNow.com. This week he covers FDA warnings on gout drugs, steroid use in Australia, biosimilars lost savings and methotrexate hepatotoxicity in psoriatic arthritis (PsA).

Stroke Increased in Rheumatoid Arthritis

Save

Rheumatoid arthritis (RA) is a chronic, inflammatory disease with systemic effects beyond the joints. While RA patients are known to have signficantly higher risks for cardiovascular disease and venous thromboembolic events, an association with stroke (CVA) is unclear.

DEA Cracks Down on Illicit Fentanyl

Save

Reuters reports that  U.S. Drug Enforcement Administration (DEA) has declaed it would classify illicit versions of fentanyl at the same level as heroin, allowing criminal prosecution of anyone who possesses, distributes or manufactures illicit versions of the drug.

Thiopurines and Anti-TNF drugs in IBD Associated with Increased Lymphoma Risk

Save

JAMA presents a French report on the cancer risk of thiopurine or tumor necrosis factor inhibitor (TNFi) use in adult patients with inflammatory bowel disease (IBD) and finds a raised risk for lymphoma in IBD compared to those not treated with these agents.  (Citation source 

MTX Doubles Hepatotoxicity Risk in Psoriasis Patients

Save

A study from the University of Pennsylvania Perelman School of Medicine was published in the Journal of Investigative Dermatology showing that the risk of incident liver disease doubled when patients with psoriasis (PsO) or psoriatic arthritis (PsA) take methotrexate (MTX), but not when

My ACR Takeaways

Save

With ACR 2017 winding down and the sheer volume of information seemingly overwhelming, I wanted to take the time to write an article regarding a few tips I learned that I will use in clinical practice.

Cardiovascular Events: Allopurinol vs. Febuxostat

Save

In the registration trials for febuxostat there were concerns about a cardiovascular (CV) safety signal. In studies of the effect of allopurinol on CV risk/events allopurinol has found to be protective so whether febuxostat is different is a point to clarify.

Comparative Risk of Biologic Therapies in RA Patients Undergoing Elective Arthroplasty

Save

During today’s plenary session Micheal D. George, et al. presented results of a study that sought to compare risk of post-op infections in RA patients undergoing arthroplasty exposed to biologic DMARDs versus methotrexate.

IL-17 Inhibition with Secukinumab in PsA: X-Ray Outcomes

Save

With the emergence of new MOAs for the treatment of psoriatic arthritis in recent years, the most burning question remained if newer agents would perform as well in terms of radiographic progression as they did in clinical domains.

Podcast of ACR17 Day 2

Save

Check out this compilation of our ACR17 Day 2 videocasts merged into a one hour podcast !

Low-dose Bactrim Safe with Methotrexate in AAV

Save

A high proportion of GPA patients receive pneumocystis prophylaxis, usually with TMP-SMX (Bactrim), and drug interactions are always a concern.  

Co-morbid Fibromyalgia

Save

ACR 2017 - Day 1 Highlights

Save

Curtis and colleagues presented a plenary session that analyzed the duration of drug holidays and the risk of subsequent fractures (FX) in women starting bisphosphonates (BP).

Increasing Incidence of Paradoxical Autoimmune Disease with Biologics?

Save

With the increasing use of biologic therapies to treat rheumatic disease has come an awareness of a small but real risk of developing de novo autoimmune disease.

Romosozumab vs Alendronate in Postmenopausal Osteoporosis

Save

Poster 318 presented at the ACR on Sunday morning caught attention of many, highlighting updates in phase 3 active controlled study of romosozumab vs alendronate in patients with postmenopausal osteoporosis with high risk of fracture.

BMS Featured Presentations from ACR 2017

Save

Bristol-Myers Squibb Company confirmed that 34 abstracts related to ORENCIA® (abatacept) and the Company’s immunoscience pipeline will be presented at the 2017 American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting, November 3-8, 2017, in San Diego.

Novartis Features Secukinumab Data at ACR 17

Save

Novartis has announce it will present its long-term 4-year data in ankylosing spondylitis (AS) and 24-weeks data in psoriatic arthritis (PsA) to be presented at the 2017 ACR/ARHP Annual Meeting

Abbvie's Robust ACR Presentations

Save

AbbVie announced that data from 38 abstracts of HUMIRA® (adalimumab) and the company's portfolio of investigational immunology medicines will be presented at the 2017 American College of Rheumatology (ACR)/Association for Rheumatology Health Professionals (ARHP) Annual Meeting, November 3-8, in S